Association of HLA Class II Alleles with Disease Severity and Treatment Response in Iranian Patients with Myasthenia Gravis

Myasthenia gravis is an autoimmune neuromuscular disease with a multifactorial etiology. A major part of the genetic susceptibility belongs to theHLAencoding genes. In this study, we investigated the role ofHLAclass II polymorphism in disease severity, and treatment response. In our 146 patients, 15 DRB1, 7DQA1, and 9DQB1 alleles, and 19 haplotypes were found. Adjusted p-values did not show any significant associations between these loci, disease severity and treatment outcome. Further studies in different populations with a larger number of patients are needed to determine the exact contribution of HLA class II alleles to MG prognosis.

Automated summary

This study investigated the role of HLA class II polymorphism in the severity and treatment response of myasthenia gravis patients, with no significant associations found between these loci and disease outcomes. Further research with larger sample sizes in diverse populations is needed to determine the exact contribution of HLA class II alleles to MG prognosis.